Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.52 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.52 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL4084810 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL11089941 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL4084806 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL11089943 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL1085708 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL23322528 | 0.97 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL5195839 | 0.97 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL5160184 | 0.97 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL317388 | 0.97 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| Aspartic Acid SCHEMBL10543254 | 0.97 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120213748-A1 | CARDIOMYOCYTES AND METHODS OF PRODUCING AND PURIFYING CARDIOMYOCYTES | NISTOR GABRIEL (US) | 2012-08-23 | — | — | US | claimed |
| EP-2139988-A1 | CARDIOMYOCYTES AND METHODS OF PRODUCING AND PURIFYING CARDIOMYOCYTES | California Stem Cell, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| EP-2079453-A1 | ROBUST SUSTAINED RELEASE FORMULATIONS | Penwest Pharmaceuticals Co. (US) | 2009-07-22 | — | — | EP | claimed |
| WO-2008112323-A1 | CARDIOMYOCYTES AND METHODS OF PRODUCING AND PURIFYING CARDIOMYOCYTES | CALIFORNIA STEM CELL, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2008045060-A1 | ROBUST SUSTAINED RELEASE FORMULATIONS | PENWEST PHARMACEUTICALS CO. (US) | 2008-04-17 | — | — | WO | claimed |
| US-20080085304-A1 | Robust sustained release formulations | PENWEST PHARMACEUTICALS CO. (US) | 2008-04-10 | — | — | US | claimed |
| EP-1526163-B1 | Method of second step polishing in copper CMP with a polishing fluid containing no oxidizing agent | ROHM & HAAS ELECT MAT (US) | 2007-08-08 | — | — | EP | claimed |
| US-20050090106-A1 | Method of second step polishing in copper CMP with a polishing fluid containing no oxidizing agent | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. | 2005-04-28 | — | — | US | claimed |
| EP-1526163-A1 | Method of second step polishing in copper CMP with a polishing fluid containing no oxidizing agent | Rohm and Haas Electronic Materials CMP Holdings, Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| EP-4739661-A1 | GTPASE INHIBITORS AND USES THEREOF | The Regents of University of California (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | UNIV CALIFORNIA (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025010415-A1 | GTPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4452416-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118786129-A | Covalent binding inhibitors of G12S, G D and/or G12E mutants of K-RAS GTPases | 加利福尼亚大学董事会 | 2024-10-15 | — | — | CN | disclosed |
| US-20010005009-A1 | Slurry for chemical mechanical polishing | NEC ELECTRONICS CORPORATION (JP) | 2001-06-28 | — | — | US | disclosed |
| EP-0980404-A1 | IMIDE-FREE AND MIXED AMIDE/IMIDE THERMAL SYNTHESIS OF POLYASPARTATE | UNIVERSITY OF SOUTH ALABAMA (US) | 2000-02-23 | — | — | EP | disclosed |
| US-5981691-A | THERMAL SYNTHESIS OF POLYASPARTATE WITHOUT FORMATION OF THE INTERMEDIATE POLYSUCCINIMIDE; HEATING SALT OF ASPARTIC ACID WITH POLYAMINE | UNIVERSITY OF SOUTH ALABAMA (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1998047964-A1 | IMIDE-FREE AND MIXED AMIDE/IMIDE THERMAL SYNTHESIS OF POLYASPARTATE | UNIVERSITY OF SOUTH ALABAMA (US) | 1998-10-29 | — | — | WO | disclosed |
| US-4988515-A | Antiischemic agents | THE REGENTS OF THE UNIV. OF CALIF. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4725645-A | USING A TRIALKYLCYANOSILANE | SOLVAY & CIE. (SOCIETE ANONYME) (BE) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | KRAS, HRAS, NRAS | GRIK1 3418/4885GRIK2 3705/4885GRM1 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.